NCT05442216
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT05442216
Title Tagraxofusp and Azaxitadine With Venetoclax in Newly Diagnosed Secondary AML After Hypomethylating Agents (TAGALONG)
Acronym TAGALONG
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Joshua Zeidner
Indications
Therapies
Age Groups: senior | adult
Covered Countries USA

Facility Status City State Zip Country Details
University of Miami RECRUITING Miami Florida 33136 United States Details
AdventHealth Orlando RECRUITING Orlando Florida 32803 United States Details
Roswell Park Cancer Institute RECRUITING Buffalo New York 14263 United States Details
University of North Carolina at Chapel Hill RECRUITING Chapel Hill North Carolina 27599 United States Details
Atrium Health Wake Forest Baptist Comprehensive Cancer Center RECRUITING Winston-Salem North Carolina 27157 United States Details
Penn Medicine Abramson Cancer Center RECRUITING Philadelphia Pennsylvania 19104 United States Details
Lifespan Health System Rhode Island Hospital RECRUITING Providence Rhode Island 46278 United States Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field